title: CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome.
abstract: The purpose of this study was to investigate whether storing mobilized peripheral blood progenitor cell (PBPC) collections overnight before CD34+ selection may delay platelet count recovery after high-dose chemotherapy and CD34+-enriched PBPC re-infusion. Lymphoma patients underwent PBPC mobilization with cyclophosphamide 4 g/m2 i.v. and G-CSF 10 microg/kg/day subcutaneously. Patients were prospectively randomized to have each PBPC collection enriched for CD34+ cells with the CellPro CEPRATE SC System either immediately or after overnight storage at 4 degrees C. Thirty-four patients were randomized to overnight storage and 34 to immediate processing of PBPC; 15 were excluded from analysis due to tumor progression or inadequate CD34+ cell mobilization. PBPC from 23 patients were stored overnight, while 30 subjects underwent immediate CD34+ selection and cryopreservation. Median yield of CD34+ enrichment was 43.6% in the immediate processing group compared to 39.1% in the overnight storage group (P = 0.339). Neutrophil recovery >500 x 10(9)/l occurred a median of 11 days (range 9-16 days) in the overnight storage group compared to 10.5 days (range 9-21 days) in the immediate processing group (P = 0.421). Median day to platelet transfusion independence was 13 (range 7-43) days in the overnight storage group vs 13.5 (range 8-35) days in those assigned to immediate processing (P = 0.933). We conclude that storage of PBPC overnight at 4 degrees C allows pooling of consecutive-day collections resulting in decreased costs and processing time without compromising neutrophil and platelet engraftment after infusion of CD34+-selected progenitor cells. Bone Marrow Transplantation(2000) 25, 559-566.
authors.affiliation: Department of Medicine, Ireland Cancer Center of Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA.
authors.forename: H M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: A L
authors.initials: AL
authors.lastname: Pecora
authors.forename: T C
authors.initials: TC
authors.lastname: Shea
authors.forename: O N
authors.initials: ON
authors.lastname: Koç
authors.forename: J M
authors.initials: JM
authors.lastname: White
authors.forename: D A
authors.initials: DA
authors.lastname: Gabriel
authors.forename: B W
authors.initials: BW
authors.lastname: Cooper
authors.forename: S L
authors.initials: SL
authors.lastname: Gerson
authors.forename: M
authors.initials: M
authors.lastname: Krieger
authors.forename: A P
authors.initials: AP
authors.lastname: Sing
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D001792:Blood Platelets / Q000276:immunology; D001793:Blood Preservation; D002452:Cell Count; D015925:Cryopreservation; D005260:Female; D006085:Graft Survival; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics* / Q000379:methods*; D006801:Humans; D007937:Leukapheresis / Q000191:economics*; D008223:Lymphoma / Q000191:economics / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology; D010976:Platelet Count; D017713:Platelet Transfusion; D011446:Prospective Studies; D014182:Transplantation, Autologous / Q000191:economics
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents